Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065114 | 1.00 | MAPK14 (0.41) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL12122662 | 0.95 | MAPK14 (0.39) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL1079025 | 0.95 | MAPK14 (0.39) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL1060500 | 0.92 | MAPK14 (0.45) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL1060497 | 0.92 | MAPK14 (0.45) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL1064869 | 0.91 | MAPK8 (0.39) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL1063879 | 0.90 | MAPK14 (0.45) | MAPK14MAPK8MAPK9MAPK10MAPK13 | |
| SCHEMBL1063630 | 0.86 | ALOX5 (0.38) | MAPK14MAPK8MAPK13MAPK12MAPK11 | |
| SCHEMBL1065100 | 0.85 | MAPK14 (0.41) | MAPK14MAPK8MAPK9MAPK10MAPK11 | |
| SCHEMBL1065174 | 0.83 | MAPK14 (0.47) | MAPK14MAPK8MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| US-7323472-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314881-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | MAPKAPK2, MAPK8, CREBBP | MAPK14 56/4885MAPK8 2/4885MAPK9 113/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | MAPK14 22/4885MAPK8 6/4885MAPK9 68/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885MAPK8 7/4885MAPK9 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.